UCB

UCB is a biopharmaceutical and specialty chemical company headquartered in Belgium, focusing on two therapeutic areas: central nervous system (CNS) diseases and immunology. In the field of CNS diseases, the company focuses on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome, and Parkinson's disease, as well as immunological conditions such as allergies, osteoporosis, Crohn's disease, rheumatoid arthritis, and systemic lupus erythematosus. UCB provides small molecule and large molecule solutions to specialists for the treatment of serious diseases. UCB also has a selective presence in primary care. The company and its subsidiaries have research and development facilities in Belgium, Germany, Japan, the UK, and the US. As of December 31, 2008, UCB had wholly-owned subsidiaries in the US, Canada, Europe, Asia, South America, and Australia.